Skip to main content
. 2016 Dec 22;27(12):1–9. doi: 10.1093/annonc/mdw307

Figure 4.

Figure 4.

K-fold cross-validation process to develop a signature and to limit overfitting in the evaluation of the magnitude of treatment benefit according to gene signature values, when only one single randomized controlled clinical trial is available.